clofibric acid has been researched along with Diabetes Mellitus in 15 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We evaluated the effect of etofibrate on the LDL-subtype distribution in patients with type 2 diabetes mellitus (n = 13, 55 +/- 18 years, BMI 27." | 5.10 | Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia. ( Dietlein, M; Geiss, HC; Parhofer, KG, 2003) |
| "Statin treatment (and possibly niacin when given alone or in combination with statins) appears to be associated with a slightly increased risk of new onset diabetes mellitus (NODM)." | 3.76 | Lipid-lowering agents and new onset diabetes mellitus. ( Athyros, VG; Karagiannis, A; Mikhailidis, DP; Tziomalos, K, 2010) |
| "Bezafibrate was well tolerated, hypoglycaemia or hypoglycaemic reactions were not observed." | 1.26 | [Improvement in diabetes control by treatment with bezafibrate]. ( Rüth, E; Vollmar, J, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (20.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wierzbicki, AS | 1 |
| Sniderman, AD | 1 |
| Athyros, VG | 1 |
| Tziomalos, K | 1 |
| Karagiannis, A | 1 |
| Mikhailidis, DP | 1 |
| Hiukka, A | 1 |
| Maranghi, M | 1 |
| Matikainen, N | 1 |
| Taskinen, MR | 1 |
| Judge, EP | 1 |
| Phelan, D | 1 |
| O'Shea, D | 1 |
| Geiss, HC | 1 |
| Dietlein, M | 1 |
| Parhofer, KG | 1 |
| Huang, JW | 1 |
| Yen, CJ | 1 |
| Chiang, HW | 1 |
| Hung, KY | 1 |
| Tsai, TJ | 1 |
| Wu, KD | 1 |
| Kon, YC | 1 |
| Pahan, K | 1 |
| Keidar, S | 1 |
| Guttmann, H | 1 |
| Stam, T | 1 |
| Fishman, I | 1 |
| Shapira, C | 1 |
| Wójcicka, G | 1 |
| Jamroz-Wiśniewska, A | 1 |
| Horoszewicz, K | 1 |
| Bełtowski, J | 1 |
| Rüth, E | 1 |
| Vollmar, J | 1 |
| Janka, HU | 1 |
| Standl, A | 1 |
| Holler, HD | 1 |
| Mehnert, H | 1 |
| Prager, R | 1 |
| Schernthaner, G | 1 |
| Kostner, GM | 1 |
| Mühlhauser, I | 1 |
| Zechner, R | 1 |
| Dorda, W | 1 |
| Takeuchi, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of a Nutritional Support System to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III[NCT04507867] | 80 participants (Actual) | Interventional | 2020-09-07 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Total number of patients with gastrointestinal symptoms at the end of follow-up at day 40.Those symptoms perceived abdominal region (pain, burn, pressure, nausea, vomiting) (NCT04507867)
Timeframe: Day 40
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 4 |
| Intervention Group | 3 |
The ratio between the water assimilated into the body and that lost from the body, in milliliters. (NCT04507867)
Timeframe: It is evaluated on day 3 of hospital stay (duration approximately 10 minutes).
| Intervention | milliliters (Mean) |
|---|---|
| Control Group | 123.4 |
| Intervention Group | 456.6 |
Patients who were intubated during their hospital stay and died before completing follow-up on day 40. (NCT04507867)
Timeframe: 40 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 5 |
| Intervention Group | 1 |
The need to continue with supplemental oxygen at hospital discharge. Categories: 1. Yes, 2. No. (NCT04507867)
Timeframe: Day 40
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 23 |
| Intervention Group | 26 |
Association between the presentation of certain laboratory parameters taken in the baseline period, with te overall mortality of discharge patients in comparison with deceased patients (NCT04507867)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Leukocytes <10x10^3/μL | 3 |
| Leukocytes >10x10^3/μL | 5 |
Association between the presentation of certain laboratory parameters taken in the baseline period, with te overall mortality of discharge patients in comparison with deceased patients (NCT04507867)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Neutrophils <80% | 0 |
| Neutrophils >80% | 8 |
Association between the presentation of certain laboratory parameters taken in the baseline period, with te overall mortality of discharge patients in comparison with deceased patients (NCT04507867)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| RCP <150 mg/L | 1 |
| RCP >150 mg/L | 7 |
Association between the presentation of certain laboratory parameters taken in the baseline period, with te overall mortality of discharge patients in comparison with deceased patients (NCT04507867)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Urea <40 mg/dL | 4 |
| Urea >40 mg/dL | 4 |
Association between the presentation of certain laboratory parameters taken at baseline with the overall mortality of discharged patients compared to deceased patients. (NCT04507867)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Fibrinogen <700 mg/dL | 2 |
| Fibrinogen >700 mg/dL | 6 |
Association between the presentation of certain laboratory parameters taken in the baseline period, with te overall mortality of discharge patients in comparison with deceased patients (NCT04507867)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Procalcitonin <0.5 ng/mL | 4 |
| Procalcitonin >0.5 ng/mL | 4 |
Association between the presentation of certain laboratory parameters taken in the baseline period, with te overall mortality of discharge patients in comparison with deceased patients (NCT04507867)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Ureic Nitrogen <22 mg/dL | 4 |
| Ureic Nitrogen >22 mg/dL | 4 |
Refers to the subjective sensation of increased abdominal pressure without an increase in abdominal size, the number of defecations were quantified at day 3 and compared between both groups. (NCT04507867)
Timeframe: Day 3
| Intervention | defecations (Mean) |
|---|---|
| Control Group | 0.81 |
| Intervention Group | 1.41 |
Is a visible increase in abdominal girth.1. Present, 2. Absent. (NCT04507867)
Timeframe: Day 3
| Intervention | percent of participants (Number) |
|---|---|
| Control Group | 51.6 |
| Intervention Group | 19.4 |
Total number of patients who died before day 40 of follow-up. (NCT04507867)
Timeframe: 40 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 7 |
| Intervention Group | 1 |
Overall survival, the total number of patients included in the study and completed a 40-day follow-up. (NCT04507867)
Timeframe: 40 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 33 |
| Intervention Group | 39 |
the total number of patients with oxygen saturation >90% on day 3 of their hospital stay. (NCT04507867)
Timeframe: day 3.
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 34 |
| Intervention Group | 37 |
"The Bristol Stool Form Scale categorizes stools into one of seven stool types ranging from type 1 (hard lumps) to type 7 (watery diarrhea). Type 3 and 4 were considered Normal." (NCT04507867)
Timeframe: day 3
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 8 |
| Intervention Group | 13 |
Persistence of clinical signs and symptoms that arise after developing COVID-19, and are not explained by an alternative diagnosis. 1. Present. 2. Absent. (NCT04507867)
Timeframe: Day 40.
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 9 |
| Intervention Group | 8 |
total number of patients included in the study who progressed to mechanical ventilation during the first 10 days of hospital stay. (NCT04507867)
Timeframe: 10 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 7 |
| Intervention Group | 3 |
The oxygen saturation without supplementary oxygen is taken at the control appointment 40 days after hospital discharge. (NCT04507867)
Timeframe: day 40
| Intervention | percentage (Mean) |
|---|---|
| Control Group | 90.39 |
| Intervention Group | 92.08 |
Total number of patients who were intubated, extubated, discharged and completes the 40 day follow-up (NCT04507867)
Timeframe: 40 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 2 |
| Intervention Group | 2 |
It is recorded for how many days the treating doctor asked the patients to continue to administer supplemental oxygen after hospital discharge (NCT04507867)
Timeframe: day 40
| Intervention | days (Mean) |
|---|---|
| Control Group | 57.6 |
| Intervention Group | 43.8 |
Is defined as at least a 5% reduction in weight from the baseline level.Total number of patients with weight loss at the end of follow-up at day 40 (NCT04507867)
Timeframe: Day 40
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 8 |
| Intervention Group | 8 |
Difference in oxygen delivery between the baseline period and day 3 of hospital stay in each group. (NCT04507867)
Timeframe: baseline and day 3
| Intervention | Liters (L) (Mean) | |
|---|---|---|
| Baseline | Day 3 | |
| Control Group | 5.9 | 6 |
| Intervention Group | 6 | 4.5 |
Is a self-administered version of the PRIME-MD diagnostic instrument for common mental disorders, includes 9 items, which evaluate the presence of depressive symptoms based on the criteria of the Diagnostic and Statistical Manual of Mental Disorders version 4, during the last 2 weeks, how often the patient presented depressive symptoms. According to the sum of the score obtained, the following 4 categories will be considered: 0-4 minimum existence or absence of depressive symptoms; 5-9 = mild depressive symptoms; 10-14 = moderate depressive symptoms; 15-19 = moderate to severe depressive symptoms; 20-27 = severe depressive symptoms. (NCT04507867)
Timeframe: baseline and hospital discharge
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Hospital discharge | |
| Control Group | 3.66 | 1.50 |
| Intervention Group | 5.3 | 1.9 |
Quick-Sequential Organ Failure Assessment (qSOFA) score gives 0 to 3 points. ≥2 in the setting of suspected infection had a high predicted in-hospital mortality rate and could be considered septic. (NCT04507867)
Timeframe: Baseline and Day 3
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Day 3 | |
| Control Group | 0.42 | 0.51 |
| Intervention Group | 0.65 | 0.43 |
5 reviews available for clofibric acid and Diabetes Mellitus
| Article | Year |
|---|---|
Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Creatinine; Diabetes Me | 2009 |
PPARalpha: an emerging therapeutic target in diabetic microvascular damage.
Topics: Clofibric Acid; Diabetes Mellitus; Dyslipidemias; Hemodynamics; Humans; Microvessels; PPAR alpha | 2010 |
Beyond statin therapy: a review of the management of residual risk in diabetes mellitus.
Topics: Atherosclerosis; Clofibric Acid; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combinatio | 2010 |
Lipid-lowering drugs.
Topics: Alzheimer Disease; Clofibric Acid; Diabetes Mellitus; Humans; Hydroxymethylglutaryl-CoA Reductase In | 2006 |
Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism.
Topics: Alzheimer Disease; Atherosclerosis; Cholesterol; Clofibric Acid; Diabetes Mellitus; DNA-Binding Prot | 2007 |
3 trials available for clofibric acid and Diabetes Mellitus
| Article | Year |
|---|---|
Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia.
Topics: Adult; Aged; Body Mass Index; Cholesterol; Cholesterol, HDL; Clofibric Acid; Diabetes Complications; | 2003 |
[Carbohydrate metabolism in bezafibrate therapy. Controlled study of glibenclamide-treated diabetics with hyperlipidemia].
Topics: Aged; Bezafibrate; Carbohydrate Metabolism; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Di | 1982 |
Effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins AI, AII and B and LCAT activity in hyperlipidemic, non-insulin-dependent diabetics.
Topics: Aged; Apolipoprotein A-II; Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Bezafibrate; Chole | 1982 |
7 other studies available for clofibric acid and Diabetes Mellitus
| Article | Year |
|---|---|
Apolipoprotein B, diabetes and medical consensus.
Topics: Apolipoproteins B; Clofibric Acid; Consensus; Diabetes Complications; Diabetes Mellitus; Diabetic An | 2010 |
Lipid-lowering agents and new onset diabetes mellitus.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus; Dyslipidemias; Evidence-Based Medicine; | 2010 |
Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function.
Topics: Adiponectin; Aged; Body Mass Index; Clofibric Acid; Coronary Vessels; Diabetes Mellitus; Echocardiog | 2004 |
High-density lipoprotein cholesterol: ready for prime time?
Topics: Cardiovascular Diseases; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Ch | 2005 |
High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate.
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Di | 2007 |
[Improvement in diabetes control by treatment with bezafibrate].
Topics: Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Diabetes Complications; Diabetes Mellitu | 1982 |
[Diabetes mellitus and secondary hyperlipidemia].
Topics: Adipose Tissue; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clofibric Acid; Diabetes Comp | 1992 |